Table 2.
Comparison of clinical and laboratory parameters according to AKI in high or low KDPI donor KTR
| Variable | High KDPI-KTR |
Low KDPI-KTR |
||||
|---|---|---|---|---|---|---|
| Non-AKI-DDKT | AKI-DDKT | p-value | Non-AKI-DDKT | AKI-DDKT | p-value | |
| Donor | 79 | 178 | 154 | 115 | ||
| Age at KT (yr) | 56.2 ± 10.0 | 54.5 ± 8.3 | 0.173 | 34.8 ± 13.7 | 36.4 ± 10.7 | 0.261 |
| Sex, male:female | 44:35 | 127:51 | 0.016 | 107:47 | 90:25 | 0.126 |
| BMI (kg/m2) | 23.3 ± 3.3 | 23.1 ± 3.1 | 0.653 | 22.2 ± 3.9 | 24.1 ± 4.0 | <0.001 |
| HTN | 41 (51.9) | 55 (30.9) | 0.002 | 8 (5.2) | 3 (2.6) | 0.362 |
| DM | 14 (17.7) | 30 (16.9) | 0.859 | 4 (2.6) | 2 (1.7) | > 0.999 |
| Cause of donor death, CVA | 56 (70.9) | 140 (78.7) | 0.024 | 92 (59.7) | 75 (65.2) | 0.377 |
| eGFR (mL/min/1.73 m2) | ||||||
| Baseline | 81.0 ± 27.0 | 45.4 ± 26.6 | <0.001 | 102.3 ± 34.5 | 59.0 ± 36.0 | <0.001 |
| At allocation | 77.7 ± 24.7 | 34.0 ± 21.0 | <0.001 | 106.7 ± 31.4 | 50.5 ± 32.0 | <0.001 |
| CKD stage 3 or above stage | 37 (46.8) | 85 (47.8) | 1 | 56 (36.4) | 56 (48.7) | 0.046 |
| ECD | 39 (49.4) | 109 (61.2) | 0.1 | 0 | 1 (0.9) | 0.428 |
| Recipient | 99 | 239 | 171 | 148 | ||
| Transplant year | 0.157 | 0.098 | ||||
| 1996–2005 | 0 (0) | 0 (0) | 7 (4.1) | 1 (0.7) | ||
| 2006–2010 | 17 (17.2) | 27 (11.3) | 34 (19.9) | 21 (14.2) | ||
| 2011–2016 | 82 (82.8) | 212 (88.7) | 130 (76.0) | 126 (85.1) | ||
| Age at KT (yr) | 51.4 ± 10.7 | 51.3 ± 9.9 | 0.878 | 47.0 ± 8.8 | 48.3 ± 10.7 | 0.261 |
| Sex, male:female | 60:39 | 141:98 | 0.809 | 103:68 | 85:63 | 0.649 |
| BMI (kg/m2) | 23.3 ± 3.4 | 23.3 ± 3.5 | 0.981 | 22.7 ± 3.2 | 23.4 ± 4.9 | 0.141 |
| HTN | 84 (84.8) | 206 (86.2) | 0.735 | 141 (82.5) | 122 (82.4) | > 0.999 |
| DM | 18 (18.2) | 64 (26.8) | 0.097 | 29 (17.0) | 26 (17.6) | 0.883 |
| Dialysis duration before KT (yr) | 7.0 ± 4.5 | 8.3 ± 13.6 | 0.895 | 9.0 ± 9.8 | 8.6 ± 7.1 | 0.728 |
| Previous KT | 6 (6.1) | 19 (7.9) | 0.652 | 18 (10.5) | 27 (18.2) | 0.054 |
| Cause of ESRD | 0.290 | 0.022 | ||||
| Glomerulonephritis | 45 (45.5) | 97 (40.6) | 95 (55.6) | 61 (41.2) | ||
| DM | 15 (15.2) | 55 (23.0) | 24 (14.0) | 20 (13.5) | ||
| HTN | 19 (19.2) | 51 (21.3) | 23 (13.5) | 22 (14.9) | ||
| Others | 20 (20.2) | 36 (15.1) | 29 (17.0) | 45 (30.4) | ||
| Cold ischemic time (min) | 250.2 ± 112.6 | 247.0 ± 121.4 | 0.828 | 262.3 ± 124.7 | 245.1 ± 135.2 | 0.257 |
| HLA mismatch number | 3.7 ± 1.6 | 3.8 ± 1.4 | 0.541 | 3.5 ± 1.5 | 3.5 ± 1.4 | 0.634 |
| Induction | <0.001 | 0.001 | ||||
| Basiliximab | 83 (83.8) | 141 (59.0) | 141 (82.5) | 98 (66.2) | ||
| ATG | 16 (16.2) | 98 (41.0) | 30 (17.5) | 50 (33.8) | ||
| Main immunosuppressant, tacrolimus:cyclosporine | 97:2 | 238:1 | 0.206 | 165:6 | 147:1 | 0.222 |
| PRA > 50% | 13 (13.1) | 37 (15.5) | 0.864 | 32 (21.6) | 32 (23.0) | 0.779 |
Data are expressed as number only, mean ± standard deviation, or number (%).
eGFR is calculated using Chronic Kidney Disease Epidemiology Collaboration.
AKI, acute kidney injury; ATG, antithymocyte globulin; BMI, body mass index; CKD, chronic kidney disease; CVA, cerebrovascular accident; DDKT, deceased donor kidney transplantation; DM, diabetes mellitus; ECD, expanded criteria donor; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease, HLA, human leukocyte antigen; HTN, hypertension; KDPI, Kidney Donor Profile Index; KT, kidney transplantation; KTR, kidney transplant recipient; PRA, panel-reactive antibody.